Ticlopidine acts by-
**Core Concept**
Ticlopidine is an antiplatelet medication that inhibits platelet aggregation by affecting the adenosine diphosphate (ADP) receptor on platelets. This action is crucial in preventing thrombotic events.
**Why the Correct Answer is Right**
Ticlopidine acts by selectively and irreversibly binding to the P2Y12 receptor on the surface of platelets. This receptor is responsible for the binding of ADP to platelets, which triggers the activation of the glycoprotein IIb/IIIa complex and subsequent platelet aggregation. By irreversibly inhibiting the P2Y12 receptor, ticlopidine prevents the platelets from responding to ADP, thereby reducing platelet aggregation and the risk of thrombotic events.
**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because ticlopidine does not act by inhibiting the cyclooxygenase (COX) enzyme, which is involved in the synthesis of thromboxane A2, a potent platelet aggregator.
**Option B:** Incorrect because ticlopidine does not act by blocking the glycoprotein IIb/IIIa receptor, which is involved in platelet aggregation but is targeted by different antiplatelet medications like abciximab.
**Option C:** Incorrect because ticlopidine does not act by inhibiting the phosphodiesterase (PDE) enzyme, which is involved in the regulation of intracellular signaling pathways but is not directly related to platelet aggregation.
**Clinical Pearl / High-Yield Fact**
Ticlopidine is a prodrug that requires metabolic conversion to its active metabolite, which is responsible for its antiplatelet effects. This makes it essential to consider the pharmacokinetics of ticlopidine when using it in clinical practice.
**Correct Answer: A. Irreversible inhibition of the P2Y12 receptor on platelets.**